Wide Ranks

MRK

Merck & Company, Inc.

103.12

Top Statistics
Market Cap 260 B Forward PE 10.87 Revenue Growth 4.40 %
Current Ratio 1.36 Trailing PE 21.57 Earnings Growth -33.30 %
Profit Margins 19.23 % Peg Ratio Dividend Yield 3.14 %
Enterprice / EBITA 12.41 Enterprise / Revenue 4.50 Price To Sales Trailing12 Months 4.13
Profitability
Profit Margins 19.23 % Operating Margins 26.20 %
Balance Sheet
Total Cash 14 B Total Cash Per Share 5.77 Total Debt 38 B
Total Debt To Equity 85.57 Current Ratio 1.36 Book Value Per Share 17.58
All Measures
Short Ratio 260.00 % Message Board Id finmb_288502 Shares Short Prior Month 26 M
Return On Equity 0.2833 City Rahway Uuid 3fd0c404-d9b9-32ea-a95e-f2db63766fb3
Previous Close 101.62 First Trade Date Epoch Utc -252322200 Book Value 17.58
Beta 0.4110 Total Debt 38 B Volume 9 M
Price To Book 5.87 Last Split Date 1 B Fifty Two Week Low 94.48
Total Cash Per Share 5.77 Total Revenue 63 B Shares Short Previous Month Date 1 B
Target Median Price 132.50 Max Age 86400 Recommendation Mean 1.71
Sand P52 Week Change 0.3133 Operating Margins 26.20 % Last Dividend Value 0.7700
Target Mean Price 130.89 Net Income To Common 12 B Ask 103.07
Short Percent Of Float 0.0104 Implied Shares Outstanding 2 B Last Fiscal Year End 1 B
Trailing Peg Ratio 7.18 % Average Daily Volume10 Day 14 M Average Volume10days 14 M
Total Cash 14 B Next Fiscal Year End 1 B Revenue Per Share 24.93
Held Percent Insiders 0.0006 Ebitda Margins 36.29 % Dividend Rate 3.24
Trailing PE 21.57 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 101.62 Target Low Price 100.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 106.12 Open 101.65 Dividend Yield 3.14 %
State NJ Free Cashflow 14 B Return On Assets 0.1053
Time Zone Short Name EST Trailing Eps 4.78 Day Low 101.68
Address1 126 East Lincoln Avenue Trailing Annual Dividend Rate 3.04 Price Hint 2
Shares Outstanding 2 B Target High Price 155.00 Website https://www.merck.com
52 Week Change 0.0062 Average Volume 10 M Earnings Quarterly Growth -33.50 %
Forward Eps 9.40 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 91.70 % Last Split Factor 1048:1000 Regular Market Day High 103.45
Is_sp_500 True Profit Margins 19.23 % Debt To Equity 85.57
Fifty Two Week High 134.63 Day High 103.45 Shares Short 26 M
Regular Market Open 101.65 Industry Key drug-manufacturers-general Bid 102.56
Earnings Growth -33.30 % Enterprise To Revenue 4.50 Revenue Growth 4.40 %
Shares Percent Shares Out 0.0104 Operating Cashflow 18 B Five Year Avg Dividend Yield 290.00 %
Currency USD Market Cap 260 B Time Zone Full Name America/New_York
Is_nasdaq_100 False Zip 07065 Payout Ratio 64.44 %
Quote Type EQUITY Industry Drug Manufacturers - General Ex Dividend Date 1 B
Regular Market Day Low 101.68 Held Percent Institutions 0.7945 Long Name Merck & Co., Inc.
Current Price 103.12 Enterprise To Ebitda 12.41 Financial Currency USD
Trailing Annual Dividend Yield 2.99 % Current Ratio 1.36 Gross Margins 76.59 %
Industry Disp Drug Manufacturers - General Number Of Analyst Opinions 26 Country United States
Float Shares 2 B Two Hundred Day Average 119.98 Ir Website http://www.merck.com/investors/home.html
Enterprise Value 284 B Price To Sales Trailing12 Months 4.13 Forward PE 10.87
Regular Market Volume 9 M Last Dividend Date 1 B Ebitda 22 B
Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Merck & Co.

, Inc. operates as a healthcare company worldwide.

It operates through two segments, Pharmaceutical and Animal Health.

The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.

vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications.

It also has licensed to develop, manufacture and  commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.

The company also has a collaboration agreement with Eisai Co.

, Ltd.

, Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co.

, Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.